Immune interventions in stroke

Nature Reviews Neurology

Volumn 11, Issue 9, 2015, Pages 524-535

  Fu, Ying ^a   Liu, Qiang ^a   Anrather, Josef ^b   Shi, Fu Dong ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b FEIL FAMILY BRAIN AND MIND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; ANTIBIOTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CEFTRIAXONE; CELECOXIB; DIPYRIDAMOLE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENLIMOMAB; FINGOLIMOD; LEVOFLOXACIN; MINOCYCLINE; NATALIZUMAB; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; ROSIGLITAZONE;

ANTIBIOTIC PROPHYLAXIS; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; BLOOD BRAIN BARRIER; BLOOD VESSEL PERMEABILITY; BRAIN EDEMA; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CELL ACTIVATION; CELL TRANSPLANTATION; CEREBROVASCULAR ACCIDENT; CLINICAL FEATURE; CYTOKINE RELEASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG PENETRATION; DRUG SAFETY; DRUG TOLERABILITY; ENCEPHALITIS; EVIDENCE BASED MEDICINE; FUNCTIONAL ASSESSMENT; HUMAN; IMMUNE DEFICIENCY; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; INFECTION; INFLAMMATION; MICROGLIA; MULTICENTER STUDY (TOPIC); MULTIPLE SCLEROSIS; NERVE CELL NECROSIS; NEUROPROTECTION; NONHUMAN; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; POST STROKE IMMUNODEFICIENCY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; SINGLE DRUG DOSE; STEM CELL TRANSPLANTATION; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; ADVERSE EFFECTS; ANIMAL; BRAIN; CEREBRAL HEMORRHAGE; CLINICAL TRIAL (TOPIC); IMMUNOLOGY; PATHOLOGY; PROCEDURES; STROKE;

ANIMALS; BRAIN; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOTHERAPY; MULTIPLE SCLEROSIS; STROKE;

EID: 84941025594     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2015.144     Document Type: Review

References (117)

1. Albers, G. W. et al. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA 283, 1145-1150 (2000
2. Lees, K. R. et al. Time to treatment with intravenous alteplase and outcome in stroke: An updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 375, 1695-1703 (2010
3. Fonarow, G. C. et al. Door to needle times for tissue plasminogen activator administration and clinical outcomes in acute ischemic stroke before and after a quality improvement initiative. JAMA 311, 1632-1640 (2014
4. Prabhakaran, S., Ruff, I. & Bernstein, R. A. Acute stroke intervention: A systematic review. JAMA 313, 1451-1462 (2015
5. Goyal, M. et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. N. Engl. J. Med. 372, 1019-1030 (2015
6. Campbell, B. C. et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N. Engl. J. Med. 372, 1009-1018 (2015
7. Kidwell, C. S. et al. A trial of imaging selection and endovascular treatment for ischemic stroke. N. Engl. J. Med. 368, 914-923 (2013
8. Broderick, J. P. et al. Endovascular therapy after intravenous t PA versus t PA alone for stroke. N. Engl. J. Med. 368, 893-903 (2013
9. Ciccone, A. et al. Endovascular treatment for acute ischemic stroke. N. Engl. J. Med. 368, 904-913 (2013
10. Berkhemer, O. A. et al. A randomized trial of intraarterial treatment for acute ischemic stroke. N. Engl. J. Med. 372, 11-20 (2015
11. OCollins, V. E. et al. 1,026 experimental treatments in acute stroke. Ann. Neurol. 59, 467-477 (2006
12. Macrez, R. et al. Stroke and the immune system: from pathophysiology to new therapeutic strategies. Lancet Neurol. 10, 471-480 (2011
13. Iadecola, C. & Anrather, J. The immunology of stroke: from mechanisms to translation. Nat. Med. 17, 796-808 (2011
14. Wang, J. Preclinical and clinical research on inflammation after intracerebral hemorrhage. Prog. Neurobiol. 92, 463-477 (2010
15. Chamorro, A. et al. The immunology of acute stroke. Nat. Rev. Neurol. 8, 401-410 (2012
16. Mracsko, E. & Veltkamp, R. Neuroinflammation after intracerebral hemorrhage. Front. Cell. Neurosci. 8, 388 (2014
17. Fu, Y. et al. Fingolimod for the treatment of intracerebral hemorrhage: A 2 arm proof of concept study. JAMA Neurol. 71, 1092-1101 (2014
18. Fu, Y. et al. Impact of an immune modulator fingolimod on acute ischemic stroke. Proc. Natl Acad. Sci. USA 111, 18315-18320 (2014
19. Elkind, M. S. Inflammatory mechanisms of stroke. Stroke 41, S3-S8 (2010
20. Marnane, M. et al. Plaque inflammation and unstable morphology are associated with early stroke recurrence in symptomatic carotid stenosis. Stroke 45, 801-806 (2014
21. Courties, G., Moskowitz, M. A. & Nahrendorf, M. The innate immune system after ischemic injury: lessons to be learned from the heart and brain. JAMA Neurol. 71, 233-236 (2014
22. Hao, J. et al. Central nervous system (CNS)-resident natural killer cells suppress Th17 responses and CNS autoimmune pathology. J. Exp. Med. 207, 1907-1921 (2010
23. Hao, J. et al. Interleukin 2/interleukin 2 antibody therapy induces target organ natural killer cells that inhibit central nervous system inflammation. Ann. Neurol. 69, 721-734 (2011
24. Stys, P. K., Zamponi, G. W., Van Minnen, J. & Geurts, J. J. Will the real multiple sclerosis please stand up?. Nat. Rev. Neurosci. 13, 507-514 (2012
25. Lucas, S. M., Rothwell, N. J. & Gibson, R. M. The role of inflammation in CNS injury and disease. Br. J. Pharmacol. 147 (Suppl. 1), S232-S240 (2006
26. Chen, G. Y. & Nunez, G. Sterile inflammation: sensing and reacting to damage. Nat. Rev. Immunol. 10, 826-837 (2010
27. Gan, Y. et al. Ischemic neurons recruit natural killer cells that accelerate brain infarction. Proc. Natl Acad. Sci. USA 111, 2704-2709 (2014
28. Gelderblom, M. et al. Temporal and spatial dynamics of cerebral immune cell accumulation in stroke. Stroke 40, 1849-1857 (2009
29. Hammond, M. D. et al. CCR2+ Ly6Chi inflammatory monocyte recruitment exacerbates acute disability following intracerebral hemorrhage. J. Neurosci. 34, 3901-3909 (2014
30. Hammond, M. D., Ambler, W. G., Ai, Y. & Sansing, L. H. alpha4 integrin is a regulator of leucocyte recruitment after experimental intracerebral hemorrhage. Stroke 45, 2485-2487 (2014
31. Liesz, A. et al. Regulatory T cells are key cerebroprotective immunomodulators in acute experimental stroke. Nat. Med. 15, 192-199 (2009
32. Allan, S. M., Tyrrell, P. J. & Rothwell, N. J. Interleukin 1 and neuronal injury. Nat. Rev. Immunol. 5, 629-640 (2005
33. Lambertsen, K. L. et al. A role for interferon-gamma in focal cerebral ischemia in mice. J. Neuropathol. Exp. Neurol. 63, 942-955 (2004
34. Seifert, H. A. et al. Pro-inflammatory interferon gamma signalling is directly associated with stroke induced neurodegeneration. J. Neuroimmune Pharmacol. 9, 679-689 (2014
35. Yilmaz, G., Arumugam, T. V., Stokes, K. Y. & Granger, D. N. Role of T lymphocytes and interferon-gamma in ischemic stroke. Circulation 113, 2105-2112 (2006
36. Doyle, K. P. et al. B lymphocyte mediated delayed cognitive impairment following stroke. J. Neurosci. 35, 2133-2145 (2015
37. Becker, K. J. et al. Autoimmune responses to the brain after stroke are associated with worse outcome. Stroke 42, 2763-2769 (2011
38. Romer, C. et al. Blocking stroke-induced immunodeficiency increases CNS antigen-specific autoreactivity but does not worsen functional outcome after experimental stroke. J. Neurosci. 35, 7777-7794 (2015
39. Meisel, C. & Meisel, A. Suppressing immunosuppression after stroke. N. Engl. J. Med. 365, 2134-2136 (2011
40. Sacco, R. L. et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N. Engl. J. Med. 359, 1238-1251 (2008
41. Amarenco, P. et al. High-dose atorvastatin after stroke or transient ischemic attack. N. Engl. J. Med. 355, 549-559 (2006
42. Zhang, R. L. et al. Anti ICAM 1 antibody reduces ischemic cell damage after transient middle cerebral artery occlusion in the rat. Neurology 44, 1747-1751 (1994
43. Enlimomab Acute Stroke Trial, I. Use of anti ICAM 1 therapy in ischemic stroke: results of the Enlimomab Acute Stroke Trial. Neurology 57, 1428-1434 (2001
44. Furuya, K. et al. Examination of several potential mechanisms for the negative outcome in a clinical stroke trial of enlimomab, a murine anti-human intercellular adhesion molecule 1 antibody: A bedside to bench study. Stroke 32, 2665-2674 (2001
45. Emsley, H. C. et al. A randomised phase II study of interleukin 1 receptor antagonist in acute stroke patients. J. Neurol. Neurosurg. Psychiatry 76, 1366-1372 (2005
46. Shyu, K. G., Chang, H. & Lin, C. C. Serum levels of intercellular adhesion molecule 1 and E selectin in patients with acute ischemic stroke. J. Neurol. 244, 90-93 (1997
47. US National Library of Medicine. ClinicalTrials.gov [online] https://clinicaltrials.gov/ct2/show/NCT00012454 (2010
48. US National Library of Medicine. ClinicalTrials.gov [online] https://clinicaltrials.gov/ct2/show/NCT00069069 (2015
49. Lampl, Y. et al. Minocycline treatment in acute stroke: An open-label, evaluator-blinded study. Neurology 69, 1404-1410 (2007
50. Fagan, S. C. et al. Minocycline to improve neurologic outcome in stroke (MINOS): A dose-finding study. Stroke 41, 2283-2287 (2010
51. US National Library of Medicine. ClinicalTrials.gov [online] https://clinicaltrials.gov/ct2/show/NCT00930020 (2013
52. Schwab, S. R. et al. Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients. Science 309, 1735-1739 (2005
53. Massberg, S. & von Andrian, U. H. Fingolimod and sphingosine 1 phosphate-modifiers of lymphocyte migration. N. Engl. J. Med. 355, 1088-1091 (2006
54. Cannon, R. E., Peart, J. C., Hawkins, B. T., Campos, C. R. & Miller, D. S. Targeting blood-brain barrier sphingolipid signalling reduces basal P glycoprotein activity and improves drug delivery to the brain. Proc. Natl Acad. Sci. USA 109, 15930-15935 (2012
55. Cohen, J. A. & Chun, J. Mechanisms of fingolimods efficacy and adverse effects in multiple sclerosis. Ann. Neurol. 69, 759-777 (2011
56. Budde, K. et al. First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J. Am. Soc. Nephrol. 13, 1073-1083 (2002
57. Wei, Y. et al. Fingolimod provides long-term protection in rodent models of cerebral ischemia. Ann. Neurol. 69, 119-129 (2011
58. Zhu, Z. et al. Combination of an immune modulator fingolimod with alteplase in acute ischemic stroke: A randomized multi-centre study. Circulation (in press). http://dx.doi.org/10.1161/CIRCULATIONAHA.115.016371
59. Liesz, A. et al. Inhibition of lymphocyte trafficking shields the brain against deleterious neuroinflammation after stroke. Brain 134, 704-720 (2011
60. Langhauser, F. et al. Blocking of a4 integrin does not protect from acute ischemic stroke in mice. Stroke 45, 1799-1806 (2014
61. Schabitz, W. R. & Dirnagl, U. Are we ready to translate T cell transmigration in stroke?. Stroke 45, 1610-1611 (2014
62. US National Library of Medicine. ClinicalTrials.gov [online] https://clinicaltrials.gov/ct2/show/NCT01955707 (2015
63. Liu, X. et al. Cell based therapies for ischemic stroke: from basic science to bedside. Prog. Neurobiol. 115, 92-115 (2014
64. Moniche, F. et al. Intra-Arterial bone marrow mononuclear cells in ischemic stroke: A pilot clinical trial. Stroke 43, 2242-2244 (2012
65. Hess, D. C. et al. A double-blind placebo-controlled clinical evaluation of MultiStem for the treatment of ischemic stroke. Int. J. Stroke 9, 381-386 (2014
66. Van Asch, C. J., Oudendijk, J. F., Rinkel, G. J. & Klijn, C. J. Early intracerebral hematoma expansion after aneurysmal rupture. Stroke 41, 2592-2595 (2010
67. Steiner, T. et al. Recommendations for the management of intracranial hemorrhage-part I: spontaneous intracerebral hemorrhage. The European Stroke Initiative Writing Committee and the Writing Committee for the EUSI Executive Committee. Cerebrovasc. Dis. 22, 294-316 (2006
68. Trabert, J. & Steiner, T. Deep vein thrombosis and lung embolisms in patients with stroke: prevention and therapy [German]. Nervenarzt 85, 1315-1325 (2014
69. Mayer, S. A. & Rincon, F. Treatment of intracerebral haemorrhage. Lancet Neurol. 4, 662-672 (2005
70. Sutherland, G. R. & Auer, R. N. Primary intracerebral hemorrhage. J. Clin. Neurosci. 13, 511-517 (2006
71. Graham, D. I., McIntosh, T. K., Maxwell, W. L. & Nicoll, J. A. Recent advances in neurotrauma. J. Neuropathol. Exp. Neurol. 59, 641-651 (2000
72. Lusardi, T. A., Wolf, J. A., Putt, M. E., Smith, D. H. & Meaney, D. F. Effect of acute calcium influx after mechanical stretch injury in vitro on the viability of hippocampal neurons. J. Neurotrauma 21, 61-72 (2004
73. Qureshi, A. I. et al. Extracellular glutamate and other amino acids in experimental intracerebral hemorrhage: An in vivo microdialysis study. Crit. Care Med. 31, 1482-1489 (2003
74. Wang, J. & Dore, S. Inflammation after intracerebral hemorrhage. J. Cereb. Blood Flow Metab. 27, 894-908 (2007
75. Aronowski, J. & Hall, C. E. New horizons for primary intracerebral haemorrhage treatment: experience from preclinical studies. Neurol. Res. 27, 268-279 (2005
76. Lin, S. et al. Haem activates TLR4-mediated inflammatory injury via MyD88/TRIF signalling pathway in intracerebral hemorrhage. J. Neuroinflammation 9, 46 (2012
77. Matsushita, H. et al. Suppression of CXCL2 upregulation underlies the therapeutic effect of the retinoid Am80 on intracerebral hemorrhage in mice. J. Neurosci. Res. 92, 1024-1034 (2014
78. Li, N. et al. Association of molecular markers with perihematomal edema and clinical outcome in intracerebral hemorrhage. Stroke 44, 658-663 (2013
79. Schellinger, P D. et al. Stroke MRI in intracerebral hemorrhage: is there a perihemorrhagic penumbra?. Stroke 34, 1674-1679 (2003
80. Zazulia, A. R. et al. Hypoperfusion without ischemia surrounding acute intracerebral hemorrhage. J. Cereb. Blood Flow Metab. 21, 804-810 (2001
81. Tapia-Perez, H. et al. Use of statins for the treatment of spontaneous intracerebral hemorrhage: results of a pilot study. Cent. Eur. Neurosurg. 70, 15-20 (2009
82. Flint, A. C. et al. Effect of statin use during hospitalization for intracerebral hemorrhage on mortality and discharge disposition. JAMA Neurol. 71, 1364-1371 (2014
83. Chu, K. et al. Celecoxib induces functional recovery after intracerebral hemorrhage with reduction of brain edema and perihematomal cell death. J. Cereb. Blood Flow Metab. 24, 926-933 (2004
84. Lee, S. H. et al. Effects of celecoxib on hematoma and edema volumes in primary intracerebral hemorrhage: A multicentre randomized controlled trial. Eur. J. Neurol. 20, 1161-1169 (2013
85. US National Library of Medicine. ClinicalTrials.gov [online] https://clinicaltrials.gov/ct2/show/NCT00827892 (2013
86. Wu, J. et al. Minocycline attenuates brain edema, brain atrophy and neurological deficits after intracerebral hemorrhage. Acta Neurochir. Suppl. 106, 147-150 (2010
87. Szymanska, A., Biernaskie, J., Laidley, D., Granter-Button, S. & Corbett, D. Minocycline and intracerebral hemorrhage: influence of injury severity and delay to treatment. Exp. Neurol. 197, 189-196 (2006
88. Wasserman, J. K. & Schlichter, L. C. Minocycline protects the blood-brain barrier and reduces edema following intracerebral hemorrhage in the rat. Exp. Neurol. 207, 227-237 (2007
89. US National Library of Medicine. ClinicalTrials.gov [online] https://clinicaltrials.gov/ct2/show/NCT01805895 (2015
90. Rolland, W. B. et al. Fingolimod reduces cerebral lymphocyte infiltration in experimental models of rodent intracerebral hemorrhage. Exp. Neurol. 241, 45-55 (2013
91. Rolland, W. B. 2nd et al. FTY720 is neuroprotective and improves functional outcomes after intracerebral hemorrhage in mice. Acta Neurochir. Suppl. 111, 213-217 (2011
92. Li, Y. J. et al. Fingolimod alters inflammatory mediators and vascular permeability in intracerebral hemorrhage. Neurosci. Bull. http://dx.doi.org/10.1007/s12264-015-1532-2
93. Ajmo, C. T. Jr et al. Blockade of adrenoreceptors inhibits the splenic response to stroke. Exp. Neurol. 218, 47-55 (2009
94. Sahota, P. et al. Changes in spleen size in patients with acute ischemic stroke: A pilot observational study. Int. J. Stroke 8, 60-67 (2013
95. Hug, A. et al. Infarct volume is a major determiner of post-stroke immune cell function and susceptibility to infection. Stroke 40, 3226-3232 (2009
96. Mracsko, E. et al. Differential effects of sympathetic nervous system and hypothalamic pituitary adrenal axis on systemic immune cells after severe experimental stroke. Brain Behav. Immun. 41, 200-209 (2014
97. Wong, C. H., Jenne, C. N., Lee, W. Y., Leger, C. & Kubes, P. Functional innervation of hepatic iNKT cells is immunosuppressive following stroke. Science 334, 101-105 (2011
98. Prass, K. et al. Stroke-induced immunodeficiency promotes spontaneous bacterial infections and is mediated by sympathetic activation reversal by poststroke T helper cell type 1-like immunostimulation. J. Exp. Med. 198, 725-736 (2003
99. Westendorp, W. F., Nederkoorn, P. J., Vermeij, J. D., Dijkgraaf, M. G. & Van De Beek, D. Post-stroke infection: A systematic review and meta-Analysis. BMC Neurol. 11, 110 (2011
100. Dziedzic, T., Slowik, A., Pera, J. & Szczudlik, A. Beta-blockers reduce the risk of early death in ischemic stroke. J. Neurol. Sci. 252, 53-56 (2007
101. Chamorro, A. et al. The Early Systemic Prophylaxis of Infection After Stroke study: A randomized clinical trial. Stroke 36, 1495-1500 (2005
102. Harms, H. et al. Preventive antibacterial therapy in acute ischemic stroke: A randomized controlled trial. PLoS ONE 3, e2158 (2008
103. Van De Beek, D. et al. Preventive antibiotics for infections in acute stroke: A systematic review and meta-Analysis. Arch. Neurol. 66, 1076-1081 (2009
104. Westendorp, W. F. et al. The Preventive Antibiotics in Stroke Study (PASS): A pragmatic randomised open-label masked endpoint clinical trial. Lancet 385, 1519-1526 (2015
105. BioMed Central. ISRCTN registry [online] http://www.isrctn.com/ISRCTN37118456 (2014
106. Zhang, L. et al. Estrogen stimulates microglia and brain recovery from hypoxia-ischemia in normoglycemic but not diabetic female mice. J. Clin. Invest. 113, 85-95 (2004
107. Neumann, J. et al. Microglia cells protect neurons by direct engulfment of invading neutrophil granulocytes: A new mechanism of CNS immune privilege. J. Neurosci. 28,5965-5975 (2008
108. Yousry, T. A. et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N. Engl. J. Med. 354, 924-933 (2006
109. Bloomgren, G. et al. Risk of natalizumab-Associated progressive multifocal leukoencephalopathy. N. Engl. J. Med. 366, 1870-1880 (2012
110. Trampe, A. K. et al. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort. Neurology 78, 1736-1742 (2012
111. Ribeiro, M J. et al. Could 18F DPA 714 PET imaging be interesting to use in the early post-stroke period?. EJNMMI Res. 4, 28 (2014
112. Santillo, A. F. et al. In vivo imaging of astrocytosis in Alzheimers disease: An 11C l deuteriodeprenyl and PIB PET study. Eur. J. Nucl. Med. Mol. Imaging 38, 2202-2208 (2011
113. Doerfler, A. et al. MR contrast agents in acute experimental cerebral ischemia: potential adverse impacts on neurologic outcome and infarction size. J. Magn. Reson. Imaging 11, 418-424 (2000
114. Rausch, M. et al. Dynamic patterns of USPIO enhancement can be observed in macrophages after ischemic brain damage. Magn. Reson. Med. 46, 1018-1022 (2001
115. Saleh, A. et al. In vivo MRI of brain inflammation in human ischaemic stroke. Brain 127, 1670-1677 (2004
116. Chamorro, A., Urra, X. & Planas, A. M. Infection after acute ischemic stroke: A manifestation of brain-induced immunodepression. Stroke 38, 1097-1103 (2007
117. Hao, J. et al. Nicotinic receptor β2 determines NK cell-dependent metastasis in a murine model of metastatic lung cancer. PLoS ONE 8, e57495 (2013